Trials / Conditions / Neoplasms, Germ Cell and Embryonal

Neoplasms, Germ Cell and Embryonal

16 registered clinical trials studyying Neoplasms, Germ Cell and Embryonal — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Spanish Series of Patients Treated With the Radionuclide Lutetium177 NCT04949282	Sociedad Española de Medicina Nuclear e Imagen Molecular	—
Unknown	External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patien NCT04697446	Blueprint Medicines Corporation	—
Terminated	A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer NCT04222972	Hoffmann-La Roche	Phase 3
Completed	Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Pati NCT04657315	CHA University	Phase 1 / Phase 2
Recruiting	HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors NCT03911388	M.D. Anderson Cancer Center	Phase 1
Terminated	Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With NCT02859415	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	Avelumab in Refractory Testicular Germ Cell Cancer. NCT03403777	National Cancer Institute, Slovakia	Phase 2
Completed	Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types NCT03012620	UNICANCER	Phase 2
Completed	Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Can NCT03037385	Hoffmann-La Roche	Phase 1 / Phase 2
Completed	Multicenter Database of Patients With Germ Cell Tumor NCT02863003	Latin American Cooperative Oncology Group	—
Withdrawn	Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metast NCT02839694	National Cancer Institute (NCI)	Phase 1
Completed	Understanding the Molecular and Genetic Differences Between Germ Cell Tumor at the Time of the Initial Diagnos NCT02679950	Nasser Hanna	—
Completed	Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor NCT02533765	Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS	Phase 2
Completed	Study of Oxaliplatin Plus Bevacizumab in Germ Cell Tumor Patients NCT00393861	Indiana University	Phase 2
Completed	Phase II Study of Oxaliplatine-Paclitaxel in Patients With Metastatic Germ Cell Tumor Refractory to Cisplatin NCT00611962	Sanofi	Phase 2
Approved For Marketing	Vorasidenib Expanded Access Program NCT05592743	Servier	—